Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
Ruklanthi de Alwisa b, Shiwei Chena, Esther Shuyi Gana, Eng Eong Ooia b c d e✉
- aProgram in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore
- bViral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore
- cSaw Swee Hock School of Public Health, National University of Singapore, Singapore
- dDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg
- eDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
TL;DRThe goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19 and discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis. (Semantic Scholar)